| Literature DB >> 35035614 |
Suru Yue1,2, Shasha Li1, Xueying Huang1, Jie Liu1, Xuefei Hou1,2, Yufeng Wang1,2, Jiayuan Wu1,2.
Abstract
BACKGROUND: Acute kidney injury (AKI) is an important complication in critically ill patients, especially in sepsis and septic shock patients. Early prediction of AKI in septic shock can provide clinicians with sufficient information for timely intervention so that improve the patients' survival rate and quality of life. The aim of this study was to establish a nomogram that predicts the risk of AKI in patients with septic shock in the intensive care unit (ICU).Entities:
Mesh:
Substances:
Year: 2022 PMID: 35035614 PMCID: PMC8758295 DOI: 10.1155/2022/9367873
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Figure 1The flowchart of patient selection. MIMIC-III: Medical Information Mort for Intensive Care III; ICU: intensive care unit; CRRT: continuous renal replacement therapy.
Baseline characteristics of the patients with septic shock.
| Characteristics | Total (n =2415) | Train cohort (n =1690) | Validation cohort (n =725) |
|
|---|---|---|---|---|
| Demographic variables | ||||
| Age (years) | 65 (55-76) | 65 (55-75) | 65 (55-77) | 0.120 |
| Gender, | 0.850 | |||
| Male | 1263 (52.30) | 886 (52.43) | 377 (52.00) | |
| Female | 1152 (47.70) | 804 (47.57) | 348 (48.00) | |
| Ethnicity, | 0.550 | |||
| Caucasian | 1796 (74.37) | 1251 (74.02) | 545 (75.17) | |
| Non-Caucasian | 619 (25.63) | 439 (25.98) | 180 (24.83) | |
| Obesity, | 0.020 | |||
| No | 2276 (94.24) | 1580 (93.49) | 696 (96.00) | |
| Yes | 619 (5.76) | 110 (6.51) | 29 (4.00) | |
| Comorbidities | ||||
| Congestive heart failure, | 0.350 | |||
| No | 1556 (64.43) | 1099 (65.03) | 457 (63.03) | |
| Yes | 859 (35.57) | 591 (34.97) | 268 (36.97) | |
| Hypertension, | 0.590 | |||
| No | 1379 (57.10) | 971 (57.46) | 408 (56.28) | |
| Yes | 1036 (42.90) | 719 (42.54) | 317 (43.72) | |
| Diabetes, | 0.660 | |||
| No | 1677 (69.44) | 1169 (69.17) | 508 (70.07) | |
| Yes | 738 (30.56) | 521 (30.83) | 217 (29.93) | |
| Medications | ||||
| Aminoglycoside, | 0.750 | |||
| No | 2266 (93.83) | 1584 (93.73) | 682 (94.07) | |
| Yes | 149 (6.17) | 106 (6.27) | 43 (5.93) | |
| Glycopeptide antibiotics, | 0.230 | |||
| No | 690 (28.57) | 495 (29.29) | 195 (26.90) | |
| Yes | 1725 (71.43) | 1195 (70.71) | 530 (73.10) | |
| NSAIDs, | 0.950 | |||
| No | 714 (29.57) | 499 (29.53) | 215 (29.66) | |
| Yes | 1701 (70.43) | 1191 (70.47) | 510 (70.34) | |
| Stain, | 0.940 | |||
| No | 1963 (81.28) | 1373(81.24) | 590 (81.38) | |
| Yes | 452 (18.72) | 317 (18.76) | 135 (18.62) | |
| ACEI/ARBs, | 0.820 | |||
| No | 961 (39.79) | 675 (39.94) | 286 (39.45) | |
| Yes | 1454 (60.21) | 1015 (60.06) | 439 (60.55) | |
| Mechanical ventilation, | 0.140 | |||
| No | 1138 (47.12) | 787 (46.57) | 351 (48.41) | |
| Yes | 1277 (52.88) | 903 (53.43) | 374 (51.59) | |
| Scoring systems | ||||
| APS III | 53 (41-68) | 53 (41-67) | 53 (41-68) | 0.830 |
| SAPS II | 41 (32-50) | 40 (31-50) | 41 (32.50-51) | 0.830 |
| Vital signs | ||||
| Heart rate (beats/minute) | 91 (80-104) | 92 (80-104) | 91 (80-103) | 0.200 |
| Systolic pressure (mmHg) | 107 (100-114) | 107 (100-115) | 107 (100-114) | 0.490 |
| Diastolic pressure (mmHg) | 57 (52-63) | 57 (51-63) | 57(52-63) | 0.710 |
| Respiratory rate (beats/minute) | 20 (17-24) | 20 (17-24) | 20 (17-24) | 0.630 |
| Temperature (°C) | 36.8 (36.4-37.3) | 36.8 (36.4-37.3) | 36.8 (36.4-37.3) | 0.370 |
| SpO2 (%) | 97.4(95.9-98.7) | 97.4 (95.9-98.6) | 97.5 (95.9-98.8) | 0.140 |
| Laboratory test | ||||
| Anion gap (mmol/l) | 14.0 (12.5-16.5) | 14.0 (12.0-16.5) | 14.0 (12.5-16.3) | 0.950 |
| Bicarbonate (mEq/l) | 22.0 (19-25.5) | 22.0 (19.0-25.5) | 22.0 (18.5-25.5) | 0.150 |
| Bilirubin (mg/dl) | 0.6 (0.4-1.3) | 0.6 (0.4-1.3) | 0.6 (0.4-1.3) | 0.180 |
| Creatinine (mg/dl) | 1.1 (0.8-1.6) | 1.1 (0.8-1.6) | 1.1 (0.8-1.6) | 0.740 |
| Chloride (mEq/l) | 105.5 (101.5-109.5) | 105.5 (101.5-109.5) | 106.0 (101.5-110.0) | 0.150 |
| Glucose (mg/dl) | 134.5 (109.5-171) | 134.5 (110.0-170.13) | 135.5 (108.5-172.8) | 0.790 |
| Lactate (mmol/l) | 30.9 (27.9-34.4) | 1.9 (1.4-2.9) | 2.0 (1.4-3.1) | 0.290 |
| Platelets (K/UL) | 217.5 (137-305) | 215.0 (135.5-305.0) | 224.50 (143.5-306.8) | 0.300 |
| Potassium (mEq/l) | 4.1 (3.8-4.6) | 4.1 (3.8-4.6) | 4.1 (3.8-4.6) | 0.870 |
| PTT (seconds) | 34.6 (29.2-43.5) | 34.7 (29.3-43.7) | 34.3 (28.9-42.93) | 0.210 |
| APTT (seconds) | 15.3 (13.6-18.35) | 15.3 (13.7-18.5) | 15.1 (13.5-18.2) | 0.150 |
| BUN (mg/dl) | 24 (15.5-38.5) | 24.0 (15.5-39.0) | 24.5 (16.0-37.5) | 0.460 |
| WBC (K/UL) | 12.7 (8.1-17.9) | 12.7 (8.0-17.9) | 12.70 (8.5-18.0) | 0.310 |
| Neutrophils (%) | 78.9 (65.7-87) | 78.7 (65.0-87.0) | 79.5 (67.0-87.0) | 0.460 |
| Lymphocytes (%) | 9 (5-15.4) | 9.0 (5.0-15.4) | 9.0 (5.0-15.5) | 0.960 |
| Culture | ||||
| Gram-positive bacteria, | 0.300 | |||
| No | 1914 (79.25) | 1344 (79.53) | 570 (78.62) | |
| Yes | 501 (20.75) | 346 (20.47) | 155 (21.38) | |
| Gram-negative bacteria, | 0.490 | |||
| No | 2122 (87.87) | 1489 (88.11) | 633 (87.31) | |
| Yes | 293 (12.13) | 201 (11.89) | 92 (12.69) | |
| AKI | 0.650 | |||
| No | 849 (35.16) | 599 (35.44) | 250 (34.48) | |
| Yes | 1566 (64.84) | 1091 (64.56) | 475 (65.52) |
NSAIDs: nonsteroidal anti-inflammatory drugs; ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; APS III: acute physiology score III; SAPS II: simplified acute physiology score II; PTT: prothrombin time; APTT: activated partial thromboplastin time; BUN: blood urea nitrogen; WBC: white blood cell; AKI: acute kidney injury.
Results of the multicollinearity diagnosis.
| Variables | Variance expansion factor |
|---|---|
| Gender | 1.13 |
| Age | 1.99 |
| Ethnicity | 1.10 |
| Congestive heart failure | 1.29 |
| Hypertension | 1.21 |
| Diabetes | 1.26 |
| Obesity | 1.13 |
| APSIII | 1.04 |
| SAPS II | 3.20 |
| Aminoglycoside | 1.08 |
| Glycopeptide antibiotics | 1.20 |
| NSAIDs | 1.17 |
| Stain | 1.17 |
| ACEI/ARBs | 1.27 |
| Heart rate | 1.55 |
| Systolic pressure | 1.68 |
| Diastolic pressure | 1.79 |
| Respiratory rate | 1.33 |
| Temperature | 1.31 |
| SpO2 | 1.22 |
| Anion gap | 3.18 |
| Bicarbonate | 3.05 |
| Bilirubin | 1.29 |
| Creatinine | 2.37 |
| Chloride | 1.95 |
| Glucose | 1.29 |
| Lactate | 1.63 |
| Platelets | 1.54 |
| Potassium | 1.23 |
| PTT | 1.15 |
| APTT | 1.17 |
| BUN | 2.23 |
| WBC | 1.19 |
| Neutrophils | 1.03 |
| Lymphocytes | 1.10 |
| Gram-positive bacteria | 1.08 |
| Gram-negative bacteria | 1.12 |
| Mechanical ventilation | 1.60 |
NSAIDs: nonsteroidal anti-inflammatory drugs; ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; APS III: acute physiology score III; SAPS II: simplified acute physiology score II; SBP: systolic blood pressure; DBP: diastolic blood pressure; PTT: prothrombin time; APTT: activated partial thromboplastin time; BUN: blood urea nitrogen; WBC: white blood cell; AKI: acute kidney injury.
Univariate logistic regression analysis of predictive variables of AKI in the training cohort.
| Variables | OR | 95% CI |
|
|---|---|---|---|
| Demographic variables | |||
| Age (years) | 1.01 | 1.17-1.89 | 0.340 |
| Female, | 1.49 | 0.99-1.02 | <0.001 |
| Non-Caucasian, | 0.59 | 0.45-0.77 | <0.001 |
| Obesity, | 2.61 | 1.02-1.76 | <0.001 |
| Comorbidities, | |||
| Congestive heart failure, | 1.34 | 0.95-1.57 | 0.030 |
| Hypertension, | 1.22 | 1.04-1.81 | 0.130 |
| Diabetes, | 1.38 | 1.43-4.78 | 0.020 |
| Interventions | |||
| Aminoglycoside, | 0.99 | 1.00-1.01 | 0.960 |
| Glycopeptide antibiotics, | 0.81 | 1.03-1.06 | 0.130 |
| NSAIDs, | 0.96 | 0.97-1.08 | 0.740 |
| Stain, | 1.25 | 0.60-1.63 | 0.180 |
| ACEI/ARBs, | 1.72 | 0.62-1.06 | <0.001 |
| Mechanical ventilation, | 1.87 | 1.41-2.47 | <0.001 |
| Scoring systems | |||
| APSIII | 1.00 | 0.73-1.25 | 0.560 |
| SAPSII | 1.05 | 0.91-1.71 | <0.001 |
| Vital signs | 1.02 | 1.34-2.21 | 0.410 |
| Heart rate (beats/minute) | 1.01 | 1.00-1.02 | 0.230 |
| Systolic pressure (mmHg) | 1.00 | 0.98-1.01 | 0.700 |
| Diastolic pressure (mmHg) | 0.99 | 0.98-1.01 | 0.420 |
| Respiratory rate (beats/minute) | 1.00 | 0.97-1.03 | 1.000 |
| Temperature (°C) | 0.85 | 0.71-1.02 | 0.090 |
| SpO2 (%) | 0.96 | 0.91-1.02 | 0.230 |
| Laboratory test | |||
| Anion gap (mmol/l) | 1.00 | 0.94-1.06 | 0.900 |
| Bicarbonate (mEq/l) | 1.03 | 0.99-1.07 | 0.130 |
| Bilirubin (mg/dl) | 1.07 | 1.03-1.13 | <0.001 |
| Creatinine (mg/dl) | 1.25 | 1.05-1.48 | 0.010 |
| Chloride (mEq/l) | 0.99 | 0.96-1.01 | 0.190 |
| Glucose (mg/dl) | 1.00 | 0.99-1.00 | 0.130 |
| Lactate (mmol/l) | 1.07 | 0.96-1.19 | 0.230 |
| Platelets (K/Ul) | 1.00 | 0.99-1.01 | 0.730 |
| Potassium (mEq/l) | 1.04 | 0.85-1.27 | 0.700 |
| PTT (seconds) | 1.00 | 0.99-1.01 | 0.230 |
| APTT (seconds) | 0.99 | 0.98-1.00 | 0.050 |
| BUN (mg/dl) | 0.99 | 0.98-1.00 | <0.001 |
| WBC (K/Ul) | 0.99 | 0.98-1.01 | 0.240 |
| Neutrophils (%) | 1.00 | 0.99-1.01 | 0.930 |
| Lymphocytes (%) | 1.00 | 0.99-1.01 | 0.310 |
| Culture | |||
| Gram positive bacteria, | 1.35 | 1.01-1.81 | 0.050 |
| Gram negative bacteria, | 1.04 | 0.71-1.52 | 0.850 |
CI: confidence interval; OR: odds ratio; NSAIDs: nonsteroidal anti-inflammatory drugs; ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; APS III: acute physiology score III; SAPS II: simplified acute physiology score II; PTT: prothrombin time; APTT: activated partial thromboplastin time; BUN: blood urea nitrogen; WBC: white blood cell; AKI: acute kidney injury.
Multivariate logistic regression analysis of risk factors of AKI in the training cohort.
| Variables | OR | 95% CI |
|
|---|---|---|---|
| Gender (female vs. male) | 1.41 | 1.13-1.77 | <0.001 |
| Ethnicity (non-Caucasian vs. Caucasian) | 0.61 | 0.47-0.78 | <0.001 |
| Congestive heart failure (yes vs. no) | 1.53 | 1.19-1.97 | <0.001 |
| Diabetes (yes vs. no) | 1.32 | 1.03-1.68 | 0.030 |
| Obesity (yes vs. no) | 2.98 | 1.66-5.34 | <0.001 |
| SAPS II | 1.05 | 1.04-1.06 | <0.001 |
| ACEI/ARBs (yes vs. no) | 1.78 | 1.40-2.25 | <0.001 |
| Bilirubin (mg/dl) | 1.08 | 1.03-1.12 | <0.001 |
| Creatinine (mg/dl) | 1.20 | 1.04-1.38 | 0.010 |
| BUN (mg/dl) | 0.99 | 0.98-0.99 | <0.001 |
| Mechanical ventilation (yes vs. no) | 1.69 | 1.33-2.15 | <0.001 |
| Constant | 0.12 | <0.001 |
OR: odds ratio; CI: confidence interval; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; SAPS II: simplified acute physiology score II; BUN: blood urea nitrogen; AKI: acute kidney injury.
Figure 2Nomogram to identify the risk of AKI in septic shock, based on logistic regression analysis. To acquire the corresponding scores for each variable, draw a vertical line upward to the “Points” axis. Sum the score for all predictors and locate the final value on the “Total Points” axis. Draw a line straight down to the “Probability of AKI” axis to determine the risk of AKI. Abbreviations: AKI: acute kidney injury; SAPS II: Simplified Acute Physiology Score II; ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; BUN: blood urea nitrogen.
Figure 3Receiver operating characteristic curve of the nomogram. Receiver operating characteristic curve for predicting AKI in septic shock patients during the intensive care admission. AUC: area under the receiver operating characteristic curve. The AUC of the nomogram for the prediction of AKI in septic shock patients was 0.756 in the training set and 0.760 in the validation set.
Figure 4Calibration curves of the predicted nomogram in the training set (a) and validation set (b). The x-axis represents the predicted probability calculated by the nomogram, and the y-axis is the observed actual probability of AKI. The clinodiagonal represents a perfect prediction by an ideal model. The solid curve represents the initial cohort and the dotted curve is bias corrected by bootstrapping (B = 1000 repetitions), which demonstrates the performance of the predicted model.
Figure 5Decision curve analysis (DCA) of the nomogram in the training set (a) and the validation set (b). The horizontal line indicates no patients develop acute kidney injury (AKI), and the gray oblique line indicates patients develop AKI. The red solid line represents the AKI risk nomogram. In DCA, the nomogram shows a more net benefit than full or no treatment across a threshold probability range. DCA: decision curve analysis; AKI: acute kidney injury.
Figure 6Clinical impact curve (CIC) of nomogram. The red curve (number of high-risk individuals) indicates the number of people who are classified as positive (high risk) by the model at each threshold probability; the blue curve (number of high-risk individuals with outcome) is the number of true positives at each threshold probability. CIC visually indicated that nomogram conferred high clinical net benefit and confirmed the clinical value.